These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 8048270

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Lipids and the progression of renal disease.
    Keane WF, O'Donnell MP, Kasiske BL, Schmitz PG.
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S69-74. PubMed ID: 16989069
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis.
    Guijarro C, Keane WF.
    Miner Electrolyte Metab; 1996 Nov; 22(1-3):147-52. PubMed ID: 8676808
    [Abstract] [Full Text] [Related]

  • 5. Hyperlipidemia and progressive renal disease.
    Keane WF, Mulcahy WS, Kasiske BL, Kim Y, O'Donnell MP.
    Kidney Int Suppl; 1991 Apr; 31():S41-8. PubMed ID: 2046270
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Therapeutic implications of lipid-lowering agents in the progression of renal disease.
    Keane WF, Kasiske BL, O'Donnell MP, Schmitz PG.
    Am J Med; 1989 Nov; 87(5N):21N-24N. PubMed ID: 2486540
    [Abstract] [Full Text] [Related]

  • 8. Cholesterol synthesis inhibitors inhibit more than cholesterol synthesis.
    Kasiske BL, O'Donnell MP, Kim Y, Atluru D, Keane WF.
    Kidney Int Suppl; 1994 Feb; 45():S51-3. PubMed ID: 8158898
    [Abstract] [Full Text] [Related]

  • 9. Lipid abnormalities in the nephrotic syndrome: the therapeutic role of statins.
    Wheeler DC.
    J Nephrol; 2001 Feb; 14 Suppl 4():S70-5. PubMed ID: 11798150
    [Abstract] [Full Text] [Related]

  • 10. Glomerular structures and lipids in progressive renal disease.
    Moorhead JF, Wheeler DC, Varghese Z.
    Am J Med; 1989 Nov; 87(5N):12N-20N. PubMed ID: 2486539
    [Abstract] [Full Text] [Related]

  • 11. Progression of renal failure: role of apolipoprotein B-containing lipoproteins.
    Attman PO, Samuelsson O, Alaupovic P.
    Kidney Int Suppl; 1997 Dec; 63():S98-101. PubMed ID: 9407433
    [Abstract] [Full Text] [Related]

  • 12. Role of increased glomerular protein traffic in the progression of renal failure.
    Bruzzi I, Benigni A, Remuzzi G.
    Kidney Int Suppl; 1997 Nov; 62():S29-31. PubMed ID: 9350674
    [Abstract] [Full Text] [Related]

  • 13. [Is hyperlipidemia a factor in the progression of renal failure?].
    Geiger H.
    Z Kardiol; 1993 Nov; 82 Suppl 4():35-8. PubMed ID: 8147060
    [Abstract] [Full Text] [Related]

  • 14. Lovastatin inhibits proliferation of rat mesangial cells.
    O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF.
    J Clin Invest; 1993 Jan; 91(1):83-7. PubMed ID: 8423236
    [Abstract] [Full Text] [Related]

  • 15. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat.
    Vogelbacher R, Wittmann S, Braun A, Daniel C, Hugo C.
    Transplantation; 2007 Dec 15; 84(11):1492-9. PubMed ID: 18091526
    [Abstract] [Full Text] [Related]

  • 16. Blood glucose and lipid control as risk factors in the progression of renal damage in type 2 diabetes.
    Nosadini R, Tonolo G.
    J Nephrol; 2003 Dec 15; 16 Suppl 7():S42-7. PubMed ID: 14733300
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Low density lipoproteins and mitogenic signal transduction processes: role in the pathogenesis of renal disease.
    Kamanna VS.
    Histol Histopathol; 2002 Apr 15; 17(2):497-505. PubMed ID: 11962755
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.